Norharmane
Based on 1 Customer Validation
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible monoamine oxidase inhibitor, with IC50 values of 6.5 and 4.7 μM for MAO-A and MAO-B, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana seedlings.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 244-63-3
- Formule: C11H8N2
- Masse moléculaire:168.20
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
MAO-B 4.7 μM (IC50) |
Microbial Metabolite |
MAO-A 6.5 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: 4
|
Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
|
10.1039/C5MD00581G |
| H9 | EC50 |
44.1 μM
Compound: 7
|
Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
|
[PMID: 11473435] |
| H9 | IC50 |
141.7 μM
Compound: 7
|
Cytotoxicity against human H9 cells
Cytotoxicity against human H9 cells
|
[PMID: 11473435] |
| HeLa | IC50 |
>100 μM
Compound: 4
|
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
|
10.1039/C5MD00581G |
| HeLa | IC50 |
15 μM
Compound: 2
|
Inhibitory activity against IkappaB kinase(IKK) isolated from HeLa cells activated with recombinant MEEK1 in an ELISA phosphorylation assay.
Inhibitory activity against IkappaB kinase(IKK) isolated from HeLa cells activated with recombinant MEEK1 in an ELISA phosphorylation assay.
|
[PMID: 12824047] |
| HeLa S3 | IC50 |
>100 μM
Compound: norharman
|
Antitumor activity against human HeLaS3 cells after 24 to 72 hrs by MTT assay
Antitumor activity against human HeLaS3 cells after 24 to 72 hrs by MTT assay
|
[PMID: 21194810] |
| HL-60 | IC50 |
>100 μM
Compound: 4
|
Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
|
10.1039/C5MD00581G |
| MCF7 | IC50 |
>100 μM
Compound: 4
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
|
10.1039/C5MD00581G |
| P388 | IC50 |
25000 ng/mL
Compound: 10
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 1791472] |
| Platelet | IC50 |
>130 μM
Compound: Norharmane
|
Antiplatelet aggregation activity against collagen-induced platelet
Antiplatelet aggregation activity against collagen-induced platelet
|
[PMID: 20329729] |
| Platelet | IC50 |
130 μM
Compound: Norharmane
|
Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation
Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation
|
[PMID: 21983333] |
| SGC-7901 | IC50 |
>100 μM
Compound: 4
|
Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay
|
10.1039/C5MD00581G |
Norharmane attenuates quinolinic acid formation by interferon-gamma-stimulated monocytes THP-1 cells and attenuates L-kynurenine formation, with IC50 values of 51 μM and 43 μM, respectively[4].
?
Norharmane has the potential for use as an antibiotic adjuvant to enhance the efficacy of conventional antibiotics to reduce pathogenic bacterial infections[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male NMRI mice (22-25 g)[3]
-
Dosage:0, 2.5, 5 and 10 mg/kg
-
Administration:IP, once
-
Result:Elicited an anxiety- and antidepressant-like behavior, and decreased locomotor activity.
Chemical Information
-
CAS No. 244-63-3
-
Appearance Solid
-
Masse moléculaire 168.20
-
Formule C11H8N2
-
Color Off-white to yellow
-
SMILES
N1C2=C(C=CC=C2)C2=C1C=NC=C2
-
Synonyms
Norharman; β-Carboline
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvant et solubilité
DMSO : 11 mg/mL (65.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.1 mg/mL (6.54 mM); Clear solution
This protocol yields a clear solution of ≥ 1.1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Herraiz T, et al. Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. Life Sci. 2006 Jan 18;78(8):795-802. [Content Brief]
[2]. López-González D, et al. A natural indole alkaloid, norharmane, affects PIN expression patterns and compromises root growth in Arabidopsis thaliana. Plant Physiol Biochem. 2020 Jun;151:378-390. [Content Brief]
[3]. Ebrahimi-Ghiri M, et al. Anxiolytic and antidepressant effects of ACPA and harmaline co-treatment. Behav Brain Res. 2019 May 17;364:296-302. [Content Brief]
[4]. Saito K, Chen CY, Masana M, Crowley JS, Markey SP, Heyes MP. 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells). Biochem J. 1993 Apr 1;291 ( Pt 1)(Pt 1):11-4. [Content Brief]
[5]. Paul BK, et al. Binding of norharmane with RNA reveals two thermodynamically different binding modes with opposing heat capacity changes. J Colloid Interface Sci. 2019 Mar 7;538:587-596. [Content Brief]
[6]. Luo HZ, et al. Inhibitory effect of norharmane on Serratia marcescens NJ01 quorum sensing-mediated virulence factors and biofilm formation. Biofouling. 2021 Feb;37(2):145-160. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.9453 mL | 29.7265 mL | 59.4530 mL | 148.6326 mL |
| 5 mM | 1.1891 mL | 5.9453 mL | 11.8906 mL | 29.7265 mL | |
| 10 mM | 0.5945 mL | 2.9727 mL | 5.9453 mL | 14.8633 mL | |
| 15 mM | 0.3964 mL | 1.9818 mL | 3.9635 mL | 9.9088 mL | |
| 20 mM | 0.2973 mL | 1.4863 mL | 2.9727 mL | 7.4316 mL | |
| 25 mM | 0.2378 mL | 1.1891 mL | 2.3781 mL | 5.9453 mL | |
| 30 mM | 0.1982 mL | 0.9909 mL | 1.9818 mL | 4.9544 mL | |
| 40 mM | 0.1486 mL | 0.7432 mL | 1.4863 mL | 3.7158 mL | |
| 50 mM | 0.1189 mL | 0.5945 mL | 1.1891 mL | 2.9727 mL | |
| 60 mM | 0.0991 mL | 0.4954 mL | 0.9909 mL | 2.4772 mL |
Norharmane Related Classifications
HY-W008566 Related Classifications
Powered by Bioz